Back to top
more

OPKO Health (OPK)

(Delayed Data from NSDQ)

$1.26 USD

1.26
3,664,499

-0.01 (-0.79%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $1.27 +0.01 (0.79%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Invest in Veeva Systems (VEEV) Now

by Zacks Equity Research

Veeva Systems' (VEEV) focus on cloud-based systems like Veeva Vault makes it a solid pick.

Zacks Equity Research

Masimo's (MASI) Preliminary Results for 2018 Cheer Investors

by Zacks Equity Research

Masimo (MASI) issues guidance for 2019. It anticipates witnessing strong contribution from its core product revenue segment.

Zacks Equity Research

Intuitive Surgical (ISRG) Up on Solid Preliminary Q4 Results

by Zacks Equity Research

Intuitive Surgical (ISRG) is likely to gain from solid da Vinci contributions in fourth-quarter 2018.

Zacks Equity Research

Allscripts (MDRX) Collaborates With Microsoft, Shares Up

by Zacks Equity Research

Allscripts' (MDRX) Veradigm unit signs a memorandum of understanding with Microsoft to develop an integrated research model.

Zacks Equity Research

Luminex's (LMNX) Preliminary Q4 Results Cheer Investors

by Zacks Equity Research

Luminex (LMNX) likely to gain from strong segmental contributions in Q4.

Zacks Equity Research

Here's Why You Should Hold Varian Medical (VAR) Stock Now

by Zacks Equity Research

Exclusion of Varian Medical's (VAR) flagship Halcyon from Section 301 tariffs lends it a competitive edge in the MedTech space.

Zacks Equity Research

Abiomed's (ABMD) Preliminary Q3 Results Cheer Investors

by Zacks Equity Research

Abiomed (ABMD) raises its fiscal 2019 guidance. The company also expects to see strong contribution from its core Impella product line.

Zacks Equity Research

Here's Why Investors Should Hold Luminex (LMNX) Stock Now

by Zacks Equity Research

Luminex (LMNX) gains from strength in the Aries platform. However, cutthroat competition in the life sciences industry is worrisome.

Zacks Equity Research

Here's Why Investors Should Hold DENTSPLY (XRAY) Stock Now

by Zacks Equity Research

DENTSPLY (XRAY) gains from strength in CAD/CAM dental imaging platform. However, sluggishness in the European business is worrisome.

Zacks Equity Research

Luminex Buys MilliporeSigma's Flow Cytometry Unit for $75M

by Zacks Equity Research

The recent buyout is likely to contribute $40-$50 million to Luminex's (LMNX) revenues in 2019.

Zacks Equity Research

Here's Why You Should Invest in PerkinElmer (PKI) Stock Now

by Zacks Equity Research

Focus on emerging markets, improving margins and encouraging guidance provide PerkinElmer (PKI) a competitive edge in the MedTech space.

Zacks Equity Research

Here's Why You Should Invest in Wright Medical (WMGI) Now

by Zacks Equity Research

A bullish outlook and a wide array of products make Wright Medical (WMGI) a promising investment pick.

Zacks Equity Research

Ecolab Inks Deal With Clearway for Renewable Power Project

by Zacks Equity Research

Ecolab's (ECL) virtual power purchase agreement with Clearway is part of a broader trend among corporate buyers. This will cover the company???s annual domestic energy use completely.

Zacks Equity Research

Here's Why Investors Should Retain CONMED (CNMD) Stock Now

by Zacks Equity Research

CONMED's (CNMD) steady focus on innovation is indicative of brighter prospects ahead. The company faces cutthroat competition in the niche space.

Zacks Equity Research

Becton, Dickinson's MAX Enteric Viral Panel Cleared by FDA

by Zacks Equity Research

Becton, Dickinson's (BDX) Diagnostic Systems portfolio lends it a competitive edge.

Zacks Equity Research

Here's Why You Should Buy Intuitive Surgical (ISRG) Now

by Zacks Equity Research

A solid outlook for 2018 and strength in robotics make Intuitive Surgical (ISRG) a promising investment pick.

Zacks Equity Research

Varian Medical's (VAR) Halcyon Excluded From Trade Tariffs

by Zacks Equity Research

Recent trade war-related talks are likely to favor Varian Medical (VAR) in the long run.

Zacks Equity Research

Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now

by Zacks Equity Research

Plethora of developments for Becton, Dickinson (BDX); headwinds apprehended in fiscal 2019.

Zacks Equity Research

Integra Rides on Global Prospects, Hurt by Escalating Costs

by Zacks Equity Research

Integra LifeSciences (IART) aims at investment openings in the Asian market for a faster business boost than in the United States and also to flourish specific parts of its international businesses.

Zacks Equity Research

Quest Diagnostics (DGX) Divests India Business to Strand

by Zacks Equity Research

Quest Diagnostics (DGX) sees lucrative prospects in the U.S. diagnostic testing market.

Zacks Equity Research

Cala Health Picks Medidata Cloud for Observational Study

by Zacks Equity Research

Medidata's (MDSO) Cloud platform sees a slew of developments in recent times.

Zacks Equity Research

Inogen Gains From Commercial Launch of Wireless Connect

by Zacks Equity Research

Inogen's (INGN) expanding product portfolio lends it a competitive edge in the respiratory care devices market.

Zacks Equity Research

Here's Why You Should Hold HealthEquity (HQY) Stock for Now

by Zacks Equity Research

HealthEquity's (HQY) fiscal third-quarter results hold promise while competition is stiff.

Zacks Equity Research

Baxter Stock up on Launch of Disposable Curved Applicator

by Zacks Equity Research

Baxter's (BAX) wide array of surgical products see lucrative market prospects.

Zacks Equity Research

Here's Why You Should Hold Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies' (COO) strong CVI segment favors the stock while a soft Fertility unit raises concern.